Bai Y, Gao XS, Qin SB, et al. Onco Targets Ther. 2018;11:2571-2579 Recently the authors found two main errata in the text that need to be corrected.
On page 2574, Response and survival outcomes section, 10th sentence, "Two-year local control rate was 85.7%. ( Figure  2B )." should read "Two-year local control rate was 57.1%. ( Figure 2B )."
On page 2575, Figure 2 legend, "(A) Kaplan-Meier plots of overall survival for all patients. One-year overall survival was 88.2%. Two-year overall survival was 55.6%. (B) KaplanMeier plots of local control for all patients. One-year local control rate was 100%. Two-year local control rate was 85.7%. (C) Patients with B90≥65% (n=19) achieved a higher local control rate than those with B90<65% (n=11) (median survival=15.2 months vs 3.5 months, CI=6.8-23.6 and 2.2-4.9 months, respectively; P=0.010). (D) Patients with B80≥90% (n=20) achieved a higher local control rate than those with B80<90% (n=10) (median survival=14.9 months vs 3.5 months, CI=3.4-26.3 and 1.8-5.2 months, respectively; P=0.045)." should read "(A) Kaplan-Meier plots of overall survival for all patients. One-year overall survival was 64.9%. Two-year overall survival was 44.5%. (B) Kaplan-Meier plots of local control for all patients. One-year local control rate was 100%. Two-year local control rate was 57.1%. (C) Patients with B90≥65% (n=19) achieved a higher local control rate than those with B90<65% (n=11) (median survival=15.2 months vs 3.5 months, CI=6.8-23.6 and 2.2-4.9 months, respectively; P=0.010). (D) Patients with B80≥90% (n=20) achieved a higher local control rate than those with B80<90% (n=10) (median survival=14.9 months vs 3.5 months, CI=3.4-26.3 and 1.8-5.2 months, respectively; P=0.045)."
On page 2576, Discussion section, last sentence "Therefore, daily SABR was applied in our article and the 2-year local control rate was as high as 85.7%, even stage IV NSCLC were 40%." should read "Therefore, daily SABR was applied in our article and the 1-year local control rate was as high as 100%, even stage IV NSCLC were 40%."
Despite the correction in the text list as above, the Figures of Kaplan-Meier plots of overall survival and local control are correct, and the error doesn`t the change the overall findings reported in the paper. We can still conclude that "This retrospective study suggests that P-SABR is feasible and well tolerated in bulky NSCLC. Local control rate is encouraging, especially for the B90≥65% group, which may due to the ability of P-SABR to optimize BED with equivalent toxicity". The authors apologize for this error.
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